CN100364565C - 一种治疗中风的中药组合物及其制备方法 - Google Patents
一种治疗中风的中药组合物及其制备方法 Download PDFInfo
- Publication number
- CN100364565C CN100364565C CNB2005101049336A CN200510104933A CN100364565C CN 100364565 C CN100364565 C CN 100364565C CN B2005101049336 A CNB2005101049336 A CN B2005101049336A CN 200510104933 A CN200510104933 A CN 200510104933A CN 100364565 C CN100364565 C CN 100364565C
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- rhizoma chuanxiong
- medicine composition
- salviae miltiorrhizae
- radix salviae
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 71
- 208000006011 Stroke Diseases 0.000 title claims abstract description 49
- 206010008190 Cerebrovascular accident Diseases 0.000 title claims abstract description 48
- 239000000203 mixture Substances 0.000 title claims abstract description 43
- 238000000034 method Methods 0.000 title claims abstract description 16
- 239000002994 raw material Substances 0.000 claims abstract description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 83
- 238000011282 treatment Methods 0.000 claims description 80
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 39
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 33
- 239000000843 powder Substances 0.000 claims description 32
- 239000007788 liquid Substances 0.000 claims description 28
- 241000237903 Hirudo Species 0.000 claims description 24
- 239000000706 filtrate Substances 0.000 claims description 24
- 238000012360 testing method Methods 0.000 claims description 19
- 239000009636 Huang Qi Substances 0.000 claims description 18
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical class CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 18
- 241000237636 Pheretima Species 0.000 claims description 16
- 239000012141 concentrate Substances 0.000 claims description 16
- 230000006837 decompression Effects 0.000 claims description 16
- 238000004064 recycling Methods 0.000 claims description 16
- 238000010992 reflux Methods 0.000 claims description 11
- 238000002156 mixing Methods 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 10
- 238000004821 distillation Methods 0.000 claims description 8
- 239000004615 ingredient Substances 0.000 claims description 8
- 239000013558 reference substance Substances 0.000 claims description 8
- 239000002904 solvent Substances 0.000 claims description 7
- 238000004809 thin layer chromatography Methods 0.000 claims description 7
- 238000005303 weighing Methods 0.000 claims description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 5
- 239000000047 product Substances 0.000 claims description 5
- 239000000741 silica gel Substances 0.000 claims description 5
- 229910002027 silica gel Inorganic materials 0.000 claims description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 4
- SMDOOINVMJSDPS-UHFFFAOYSA-N Astragaloside Natural products C1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)OC2C(C(OC3C(C(O)C(O)C(CO)O3)O)C(O)C(CO)O2)O)=C1 SMDOOINVMJSDPS-UHFFFAOYSA-N 0.000 claims description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 4
- QMNWISYXSJWHRY-XWJCTJPOSA-N astragaloside Chemical compound O1[C@H](C(C)(O)C)CC[C@]1(C)[C@@H]1[C@@]2(C)CC[C@]34C[C@]4(CC[C@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)CO4)O)C4(C)C)C4[C@@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)CC3[C@]2(C)C[C@@H]1O QMNWISYXSJWHRY-XWJCTJPOSA-N 0.000 claims description 4
- 235000019640 taste Nutrition 0.000 claims description 4
- 229920002472 Starch Polymers 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- 238000009472 formulation Methods 0.000 claims description 3
- 238000003908 quality control method Methods 0.000 claims description 3
- 239000007921 spray Substances 0.000 claims description 3
- 239000008107 starch Substances 0.000 claims description 3
- 235000019698 starch Nutrition 0.000 claims description 3
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 claims description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 claims description 2
- 206010037660 Pyrexia Diseases 0.000 claims description 2
- 239000002390 adhesive tape Substances 0.000 claims description 2
- 230000000274 adsorptive effect Effects 0.000 claims description 2
- 229910021529 ammonia Inorganic materials 0.000 claims description 2
- 235000011114 ammonium hydroxide Nutrition 0.000 claims description 2
- SIHHLZPXQLFPMC-UHFFFAOYSA-N chloroform;methanol;hydrate Chemical compound O.OC.ClC(Cl)Cl SIHHLZPXQLFPMC-UHFFFAOYSA-N 0.000 claims description 2
- 239000003480 eluent Substances 0.000 claims description 2
- 238000010828 elution Methods 0.000 claims description 2
- 239000011521 glass Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000007902 hard capsule Substances 0.000 claims description 2
- 239000006210 lotion Substances 0.000 claims description 2
- 229920005989 resin Polymers 0.000 claims description 2
- 239000011347 resin Substances 0.000 claims description 2
- 229920006395 saturated elastomer Polymers 0.000 claims description 2
- 239000007901 soft capsule Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 238000005406 washing Methods 0.000 claims description 2
- 239000008280 blood Substances 0.000 abstract description 35
- 210000004369 blood Anatomy 0.000 abstract description 35
- 206010008118 cerebral infarction Diseases 0.000 abstract description 9
- 208000024891 symptom Diseases 0.000 abstract description 9
- 206010019468 Hemiplegia Diseases 0.000 abstract description 7
- 230000007812 deficiency Effects 0.000 abstract description 7
- 230000017531 blood circulation Effects 0.000 abstract description 6
- 208000026106 cerebrovascular disease Diseases 0.000 abstract description 4
- 238000011084 recovery Methods 0.000 abstract description 3
- 230000001737 promoting effect Effects 0.000 abstract description 2
- 241001061264 Astragalus Species 0.000 abstract 1
- 235000010110 Astragalus glycyphyllos Nutrition 0.000 abstract 1
- 241000545744 Hirudinea Species 0.000 abstract 1
- 240000007164 Salvia officinalis Species 0.000 abstract 1
- 208000012886 Vertigo Diseases 0.000 abstract 1
- 201000007201 aphasia Diseases 0.000 abstract 1
- 235000006533 astragalus Nutrition 0.000 abstract 1
- 241001233061 earthworms Species 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 235000005412 red sage Nutrition 0.000 abstract 1
- 231100000889 vertigo Toxicity 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 24
- 230000000694 effects Effects 0.000 description 22
- 239000000243 solution Substances 0.000 description 21
- 150000001875 compounds Chemical class 0.000 description 19
- 230000002490 cerebral effect Effects 0.000 description 18
- 210000004556 brain Anatomy 0.000 description 14
- 229940079593 drug Drugs 0.000 description 14
- 230000010354 integration Effects 0.000 description 11
- 208000007536 Thrombosis Diseases 0.000 description 10
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- 210000001367 artery Anatomy 0.000 description 8
- 201000006474 Brain Ischemia Diseases 0.000 description 7
- 208000000059 Dyspnea Diseases 0.000 description 7
- 206010013975 Dyspnoeas Diseases 0.000 description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 7
- 238000003745 diagnosis Methods 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 206010016256 fatigue Diseases 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 208000013220 shortness of breath Diseases 0.000 description 7
- 206010008120 Cerebral ischaemia Diseases 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- 206010061216 Infarction Diseases 0.000 description 6
- 230000001154 acute effect Effects 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 208000002173 dizziness Diseases 0.000 description 6
- 230000007574 infarction Effects 0.000 description 6
- 230000008961 swelling Effects 0.000 description 6
- 210000001364 upper extremity Anatomy 0.000 description 6
- 206010021143 Hypoxia Diseases 0.000 description 5
- 230000003213 activating effect Effects 0.000 description 5
- 239000003146 anticoagulant agent Substances 0.000 description 5
- 230000003727 cerebral blood flow Effects 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 230000003203 everyday effect Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000002496 gastric effect Effects 0.000 description 5
- 238000001802 infusion Methods 0.000 description 5
- 230000000302 ischemic effect Effects 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 241000282472 Canis lupus familiaris Species 0.000 description 4
- 241000905957 Channa melasoma Species 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- 210000004394 hip joint Anatomy 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000029058 respiratory gaseous exchange Effects 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 208000011580 syndromic disease Diseases 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 206010002091 Anaesthesia Diseases 0.000 description 3
- 206010014080 Ecchymosis Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
- 230000037005 anaesthesia Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 229940127219 anticoagulant drug Drugs 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000008034 disappearance Effects 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 230000007954 hypoxia Effects 0.000 description 3
- 238000010253 intravenous injection Methods 0.000 description 3
- 230000036513 peripheral conductance Effects 0.000 description 3
- 230000035699 permeability Effects 0.000 description 3
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 3
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 3
- 230000035900 sweating Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 239000008727 tongluo Substances 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- 206010000087 Abdominal pain upper Diseases 0.000 description 2
- 206010048962 Brain oedema Diseases 0.000 description 2
- 206010008132 Cerebral thrombosis Diseases 0.000 description 2
- 208000027219 Deficiency disease Diseases 0.000 description 2
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 2
- AIGAZQPHXLWMOJ-UHFFFAOYSA-N Tanshinone I Chemical compound C1=CC2=C(C)C=CC=C2C(C(=O)C2=O)=C1C1=C2C(C)=CO1 AIGAZQPHXLWMOJ-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 230000000702 anti-platelet effect Effects 0.000 description 2
- 230000002146 bilateral effect Effects 0.000 description 2
- 230000036770 blood supply Effects 0.000 description 2
- 208000006752 brain edema Diseases 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 210000001168 carotid artery common Anatomy 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000035487 diastolic blood pressure Effects 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 210000001105 femoral artery Anatomy 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 239000008899 fufang danshen Substances 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 238000007373 indentation Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000003141 lower extremity Anatomy 0.000 description 2
- 239000012567 medical material Substances 0.000 description 2
- 230000003387 muscular Effects 0.000 description 2
- 229960001412 pentobarbital Drugs 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 208000037920 primary disease Diseases 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000033764 rhythmic process Effects 0.000 description 2
- 210000000323 shoulder joint Anatomy 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 230000035488 systolic blood pressure Effects 0.000 description 2
- 210000001226 toe joint Anatomy 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 230000008728 vascular permeability Effects 0.000 description 2
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 1
- 208000035657 Abasia Diseases 0.000 description 1
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 206010003658 Atrial Fibrillation Diseases 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- 240000001307 Myosotis scorpioides Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 241000233855 Orchidaceae Species 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 208000035286 Spontaneous Remission Diseases 0.000 description 1
- 229930183118 Tanshinone Natural products 0.000 description 1
- 208000032109 Transient ischaemic attack Diseases 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 230000001166 anti-perspirative effect Effects 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 239000003213 antiperspirant Substances 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 206010003230 arteritis Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 210000000269 carotid artery external Anatomy 0.000 description 1
- 210000004004 carotid artery internal Anatomy 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 229940084954 dexamethasone 1 mg Drugs 0.000 description 1
- 238000012850 discrimination method Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- -1 every day 1 time Substances 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 210000001097 facial muscle Anatomy 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 230000001723 fibrinogenic effect Effects 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 210000001624 hip Anatomy 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 239000003667 hormone antagonist Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 230000007659 motor function Effects 0.000 description 1
- 230000004220 muscle function Effects 0.000 description 1
- 208000018389 neoplasm of cerebral hemisphere Diseases 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 229960000715 nimodipine Drugs 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- DHRLEVQXOMLTIM-UHFFFAOYSA-N phosphoric acid;trioxomolybdenum Chemical compound O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.OP(O)(O)=O DHRLEVQXOMLTIM-UHFFFAOYSA-N 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 210000001034 respiratory center Anatomy 0.000 description 1
- 208000004124 rheumatic heart disease Diseases 0.000 description 1
- 238000007560 sedimentation technique Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 210000002105 tongue Anatomy 0.000 description 1
- 201000010875 transient cerebral ischemia Diseases 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 238000004879 turbidimetry Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000002385 vertebral artery Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
Description
组别 | 伊文思兰含量(μg/g脑重) |
正常对照脑缺血模型脑血康20ml/kg复方丹蛭5.4/kg复方丹蛭3.6g/kg复方丹蛭1.8g/kg | 8.58±0.7210.30±1.928.43±2.007.21±1.488.04±2.148.42±2.64 |
组别 | 脑指数(脑重g/100g体重) | 脑含水量(%) |
正常对照脑缺血模型脑血康20ml/kg复方丹蛭5.4/kg复方丹蛭3.6g/kg复方丹蛭1.8g/kg | 0.616±0.051<sup>**</sup>0.694±0.0520.629±0.073<sup>*</sup>0.607±0.052<sup>**</sup>0.638±0.042<sup>*</sup>0.634±0.036<sup>*</sup> | 78.57±0.47<sup>**</sup>79.37±0.7478.631±0.53<sup>*</sup>78.53±0.41<sup>**</sup>78.39±0.40<sup>**</sup>78.63±0.54<sup>*</sup> |
组别 | 呼吸次数 | 维持时间(秒) |
正常对照脑血康20ml/kg复方丹蛭5.4/kg复方丹蛭3.6g/kg | 6.6±2.510.2±4.0<sup>*</sup>11±3.9<sup>**</sup>12.4±3.4<sup>***</sup> | 22.5±5.227.4±4.0<sup>*</sup>32.5±6.2<sup>**</sup>35.8±10.2<sup>**</sup> |
复方丹蛭1.8g/kg | 10.8±4.1<sup>*</sup> | 33.7±6.0<sup>**</sup> |
组别 | 血管堵塞时间(分) |
正常对照脑血康20ml/kg复方丹蛭5.4/kg复方丹蛭3.6g/kg复方丹蛭1.8g/kg | 6.09±2.498.65±2.05<sup>*</sup>9.52±2.16<sup>**</sup>10.8±3.13<sup>*</sup>8.10±2.16 |
总数 | 总有效例(%) | 总显效例(%) | 基本治愈例(%) | 显效例(%) | 有效例(%) | 无效例(%) | |
治疗组 | 304 | 280(92.11) | 166(54.61) | 38(12.50) | 128(42.11) | 114(37.50) | 24(7.89) |
对照组 | 105 | 94(89.52) | 37(35.24) | 8(7.62) | 29(27.62) | 57(54.29) | 11(10.48) |
治疗组 | 对照组 | |||||||
疗前 | 疗后 | 缓解率(%) | 疗前 | 疗后 | 缓解率(%) | X2 | P | |
舌强言蹇或不语 | 244 | 38 | 84.43 | 92 | 23 | 75.00 | 0.058 | >0.05 |
上肢肩关节障碍 | 303 | 29 | 90.43 | 105 | 18 | 82.26 | 3.386 | >0.05 |
上肢指关节障碍 | 303 | 59 | 80.53 | 104 | 32 | 69.23 | 5.060 | <0.05 |
下肢髋关节障碍 | 302 | 28 | 90.73 | 104 | 21 | 79.81 | 7.695 | <0.01 |
下肢趾关节障碍 | 300 | 76 | 74.67 | 104 | 34 | 67.31 | 1.756 | >0.05 |
综合功能障碍 | 304 | 38 | 87.50 | 105 | 28 | 73.33 | 10.55 | <0.01 |
治疗组 | 对照组 | |||||||
疗前 | 疗后 | 缓解率(%) | 疗前 | 疗后 | 缓解率(%) | X2 | P | |
半身不遂 | 299 | 209 | 30.10 | 105 | 87 | 17.14 | 6.016 | <0.05 |
偏身麻木 | 265 | 135 | 49.06 | 92 | 62 | 32.61 | 6.82 | <0.01 |
口舌歪斜 | 210 | 57 | 38.57 | 80 | 61 | 23.75 | 4.99 | <0.05 |
头晕 | 235 | 79 | 66.38 | 88 | 48 | 45.45 | 10.53 | <0.05 |
气短乏力 | 272 | 111 | 59.19 | 96 | 61 | 36.46 | 13.83 | <0.01 |
面色无华 | 196 | 88 | 55.10 | 61 | 42 | 31.15 | 9.743 | <0.01 |
自汗 | 184 | 53 | 71.20 | 61 | 33 | 45.90 | 11.78 | <0.01 |
手足肿胀 | 118 | 44 | 62.71 | 40 | 24 | 40.00 | 5.393 | <0.05 |
舌质暗 | 240 | 177 | 26.25 | 84 | 66 | 21.43 | 0.536 | > |
淡 | 0.05 | |||||||
舌质瘀斑 | 116 | 67 | 42.24 | 31 | 24 | 22.58 | 3.219 | >0.05 |
舌苔薄白 | 172 | 216 | 61 | 67 | ||||
舌苔白 | 124 | 66 | 46.77 | 43 | 32 | 25.58 | 9.732 | <0.01 |
脉沉 | 153 | 117 | 23.53 | 61 | 53 | 13.11 | 2.294 | >0.05 |
脉细 | 202 | 170 | 15.84 | 63 | 53 | 15.87 | 0.037 | >0.05 |
脉弱 | 93 | 60 | 35.48 | 33 | 25 | 24.24 | 0.937 | >0.05 |
脉涩 | 44 | 27 | 38.64 | 12 | 7 | 41.67 | 0.02 | >0.05 |
例 | 疗前积分 | 疗后积分 | 治疗前后积 | t | P |
数 | 分差 | |||||
治疗组 | 304 | 15.01±2.67 | 7.42±4.27 | 7.39±3.41 | 26.28 | <0.01 |
对照组 | 105 | 14.98±3.26 | 8.76±4.32 | 6.99±3.51 | 11.78 | <0.01 |
t | 0.094 | 2.764 | 1.028 | |||
P | <0.05 | <0.05 | <0.05 |
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2005101049336A CN100364565C (zh) | 2005-09-22 | 2005-09-22 | 一种治疗中风的中药组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2005101049336A CN100364565C (zh) | 2005-09-22 | 2005-09-22 | 一种治疗中风的中药组合物及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1820770A CN1820770A (zh) | 2006-08-23 |
CN100364565C true CN100364565C (zh) | 2008-01-30 |
Family
ID=36922439
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2005101049336A Active CN100364565C (zh) | 2005-09-22 | 2005-09-22 | 一种治疗中风的中药组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100364565C (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101411742B (zh) * | 2008-11-18 | 2011-08-03 | 山西振东开元制药有限公司 | 芪蛭通络胶囊 |
CN102526255A (zh) * | 2012-02-16 | 2012-07-04 | 关秀敏 | 一种用于治疗脑出血后遗症康复的药物及其制备方法 |
CN114617939B (zh) * | 2021-12-31 | 2023-08-15 | 辽宁省血栓病中西医结合医疗中心 | 一种用于治疗缺血性脑卒中的中药制剂 |
CN114869956B (zh) * | 2022-02-11 | 2023-09-22 | 福建中医药大学附属人民医院(福建省人民医院) | 一种用于治疗脑卒中后运动功能障碍药物组合物及其制备方法和用途 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1457827A (zh) * | 2003-04-03 | 2003-11-26 | 荆应彬 | 瘫消康胶囊 |
-
2005
- 2005-09-22 CN CNB2005101049336A patent/CN100364565C/zh active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1457827A (zh) * | 2003-04-03 | 2003-11-26 | 荆应彬 | 瘫消康胶囊 |
Non-Patent Citations (1)
Title |
---|
通络愈瘫胶囊治疗脑血栓形成的临床研究. 马云枝,张运克,杨守峰.实用中西医结合杂志,第11卷第5期. 1998 * |
Also Published As
Publication number | Publication date |
---|---|
CN1820770A (zh) | 2006-08-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103169928B (zh) | 治疗痛经的外用中药组合物及其制备方法和应用 | |
CN100404035C (zh) | 一种治疗心脑血管疾病的中药组合物 | |
CN102178800B (zh) | 一种治疗类风湿性关节炎的中药组合物及其制备方法 | |
CN101773551B (zh) | 一种用于治疗软组织损伤的蒙药外用药物组合物 | |
CN104689226A (zh) | 一种治疗小儿类风湿性关节炎的中药组合物及其制备方法 | |
CN102166278A (zh) | 一种治疗小儿类风湿性关节炎的中药组合物及其制备方法 | |
CN108186877A (zh) | 用于气虚血瘀证心肌梗死二级预防的中药组合物 | |
CN100364565C (zh) | 一种治疗中风的中药组合物及其制备方法 | |
CN100333750C (zh) | 一种治疗胸痹、心悸的中药制剂及制备方法 | |
CN107648479A (zh) | 一种用于治疗高血压的中药组方及其制品 | |
CN105943705A (zh) | 一种治疗类风湿性关节炎的中药组合物及其制备方法 | |
CN105582274A (zh) | 一种治疗女性更年期综合征的药物组合物及其制备方法 | |
CN102048913B (zh) | 一种治疗更年期综合症的中药制剂及其制备方法 | |
CN101342223B (zh) | 玉蝴蝶美容祛斑膏及其制备方法 | |
CN101569682B (zh) | 治疗风湿性关节炎的药物组合物及制备方法 | |
CN103191371B (zh) | 一种预防/治疗呼吸***疾病的药物组合物及其用途 | |
CN103768307B (zh) | 一种治疗中风后肢体麻木的中药及其制备方法 | |
CN102204956B (zh) | 一种用于中风恢复期的中药组合物及其制备方法 | |
CN104740579B (zh) | 经前安片及其制备工艺 | |
CN103316270B (zh) | 一种治疗产后***粘膜病变药物的散剂制备方法 | |
CN112138105B (zh) | 一种治疗支气管扩张症肺脾气虚、痰湿阻肺证的中药组合物及其应用 | |
CN114869956B (zh) | 一种用于治疗脑卒中后运动功能障碍药物组合物及其制备方法和用途 | |
CN116270839B (zh) | 一种治疗类风湿关节炎、强直性脊柱炎的中药组合物及其制备方法与应用 | |
CN105726754A (zh) | 一种含有艾叶的治疗失血性休克的中药组合物及其制备方法 | |
CN108114106A (zh) | 一种舒筋活血消瘀止痛的中药组合物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract |
Assignee: Tonghua Baishan Pharmaceutical Ltd Assignor: Hua Yuqiang Contract record no.: 2011220000004 Denomination of invention: Chinese medicine composition for treating apoplexy and its preparing method Granted publication date: 20080130 License type: Exclusive License Open date: 20060823 Record date: 20110104 |
|
TR01 | Transfer of patent right |
Effective date of registration: 20170424 Address after: 134100 Tonghua, Sichuan Province, Tonghua Qu Chuan Development Zone, Jilin Patentee after: Tonghua Baishan Pharmaceutical Ltd Address before: 134100 Tonghua province unity Road, Jilin, No. 3333 Patentee before: Hua Yuqiang |
|
TR01 | Transfer of patent right |